Analyst Roanna Ruiz from Leerink Partners maintained a Hold rating on Amarin (AMRN – Research Report) and increased the price target to $9.00 from $1.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Roanna Ruiz’s rating is based on a combination of factors influencing Amarin’s current market position. The recent 1-for-20 ADS ratio change has improved Amarin’s compliance with NASDAQ, effectively reducing the share count and contributing to an increased price target of $9. Additionally, there is a noticeable rise in European revenues for Vazkepa, attributed to enhanced market access and growing adoption in countries with established pricing and reimbursement frameworks.
Despite these positive developments, Roanna maintains a Hold rating due to persistent challenges in the US market, where Vascepa faces significant competition from generic alternatives. While there is potential for growth if European revenues continue to increase, the current market dynamics in the US present a cautious outlook, prompting a neutral stance until more substantial evidence of revenue inflection is observed.
According to TipRanks, Ruiz is an analyst with an average return of -14.6% and a 28.76% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Cormedix, Cytokinetics, and Lantheus.